Does Glaucoma Cause Loss of Brain Function?
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to determine if glaucoma is associated with neurodegenerative changes in areas of the brain other than the occipital lobe. This will help guide the direction of further research in the use of neuroprotective agents in preventing or controlling such changes. The final goal is to improve the quality of life for patients with glaucoma.
| Condition |
|---|
|
Glaucoma |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Neuroimaging Brain Changes in Glaucoma |
- Brain atrophy [ Time Frame: 2 days ] [ Designated as safety issue: No ]Mini-Mental State Exam and T-1 weighted MRI brain scan and will be performed
| Enrollment: | 37 |
| Study Start Date: | August 2010 |
| Study Completion Date: | March 2012 |
| Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Glaucoma Patients
Patients who were outliers from the AARV or ADREV Studies.
|
|
Control Patients
Age, gender and race matched group of healthy individuals with no ocular diseases.
|
Detailed Description:
Death of retinal ganglion cells causes loss of neurons in areas other than just the visual cortex. These neurodegenerative changes decrease the patient's ability to perform the activities of daily living. Tensor-based morphometry analysis of MRI brain scans will reveal areas of cortical degeneration in glaucoma patients, and the extent of damage in these areas will correlate with their ability to perform vision-dependent tasks, as measured by the Assessment of Ability Related to Vision (AARV).
Patients with glaucoma who were outliers in Assessment of Ability Related to Vision (AARV) Study or Assessment of Disability related to vision (ADREV) Study, in that they have poor performance-based measure scores despite having midrange visual field scores.
Mini-Mental State Exam and T-1 weighted MRI brain scan and will be performed.
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Glaucoma Service, Wills Eye Institute
Inclusion Criteria:
- Patients with glaucoma who were outliers in Assessment of Ability Related to Vision (AARV) or Assessment of Disability related to vision (ADREV), in that they have poor performance-based measure scores (≤ 40s) despite having midrange visual field scores (mean deviation of -6 to -20).
- Age-, gender- and race-matched controls who do not have glaucoma, and who do not have loss of vision for any reason other than cataract or refractive error.
Exclusion Criteria:
- Patients with any type of neurological disease.
- Patients with a cognitive deficit which would affect visual functioning, as revealed by the neuro-ophthalmologic examination.
Contacts and Locations| United States, Pennsylvania | |
| Wills Eye Institute, Glaucoma Service | |
| Philadelphia, Pennsylvania, United States, 19107 | |
| Principal Investigator: | George L Spaeth, MD | Glaucoma Service, Wills Eye Institute |
More Information
No publications provided
| Responsible Party: | George L. Spaeth MD, Principal Investigator, Wills Eye |
| ClinicalTrials.gov Identifier: | NCT01303939 History of Changes |
| Other Study ID Numbers: | 10-009 |
| Study First Received: | February 24, 2011 |
| Last Updated: | April 18, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Wills Eye:
|
Glaucoma MRI Brain Scan |
Additional relevant MeSH terms:
|
Glaucoma Ocular Hypertension Eye Diseases |
ClinicalTrials.gov processed this record on May 22, 2013